<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="courier ; font-style : italic;} Clin Infect DisClin. Infect. DiscidClinical" exact="Infectious" post="Diseases: An Official Publication of the Infectious Diseases Society"/>
 <result pre="DisClin. Infect. DiscidClinical Infectious Diseases: An Official Publication of the" exact="Infectious" post="Diseases Society of America1058-48381537-6591Oxford University PressUS pmcid: 7184357 doi:"/>
 <result pre="Infect. DiscidClinical Infectious Diseases: An Official Publication of the Infectious" exact="Diseases" post="Society of America1058-48381537-6591Oxford University PressUS pmcid: 7184357 doi: 10.1093/cid/ciaa453ciaa453"/>
 <result pre="Articles and Commentaries: AcademicSubjects/MED00290 Weak Induction of Interferon Expression by" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of"/>
 <result pre="and Commentaries: AcademicSubjects/MED00290 Weak Induction of Interferon Expression by Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-Î»"/>
 <result pre="Commentaries: AcademicSubjects/MED00290 Weak Induction of Interferon Expression by Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-Î» to"/>
 <result pre="AcademicSubjects/MED00290 Weak Induction of Interferon Expression by Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 Supports Clinical Trials of Interferon-Î» to Treat"/>
 <result pre="2 Supports Clinical Trials of Interferon-Î» to Treat Early Coronavirus" exact="Disease" post="2019 Oâ€™BrienThomas R1ThomasDavid L2JacksonSarah S1Prokunina-OlssonLudmila3DonnellyRaymond P4HartmannRune5[1], Infections and Immunoepidemiology"/>
 <result pre="Treat Early Coronavirus Disease 2019 Oâ€™BrienThomas R1ThomasDavid L2JacksonSarah S1Prokunina-OlssonLudmila3DonnellyRaymond P4HartmannRune5[1]," exact="Infections" post="and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics,"/>
 <result pre="R1ThomasDavid L2JacksonSarah S1Prokunina-OlssonLudmila3DonnellyRaymond P4HartmannRune5[1], Infections and Immunoepidemiology Branch, Division of" exact="Cancer" post="Epidemiology and Genetics, National Cancer Institute, National Institutes of"/>
 <result pre="and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National" exact="Cancer" post="Institute, National Institutes of HealthUSA[2], Johns Hopkins University, School"/>
 <result pre="University, School of MedicineUSA[3], Laboratory of Translational Genomics, Division of" exact="Cancer" post="Epidemiology and Genetics, National Cancer InstituteUSA[4], Division of Biotechnology"/>
 <result pre="of Translational Genomics, Division of Cancer Epidemiology and Genetics, National" exact="Cancer" post="InstituteUSA[4], Division of Biotechnology Research and Review II, Center"/>
 <result pre="Biology and Genetics, University of AarhusDenmark Correspondence: T. R. Oâ€™Brien," exact="Infections" post="and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics,"/>
 <result pre="Correspondence: T. R. Oâ€™Brien, Infections and Immunoepidemiology Branch, Division of" exact="Cancer" post="Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center"/>
 <result pre="and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National" exact="Cancer" post="Institute, 9609 Medical Center Dr, 6E108, MSC 9767, Bethesda,"/>
 <result pre="public domain in the US.ciaa453.pdf innate immunity MERS-CoV SARS-CoV severe" exact="acute" post="respiratory syndrome virology Funding National Institutes of Health10.13039/100000002 Division"/>
 <result pre="domain in the US.ciaa453.pdf innate immunity MERS-CoV SARS-CoV severe acute" exact="respiratory" post="syndrome virology Funding National Institutes of Health10.13039/100000002 Division of"/>
 <result pre="in the US.ciaa453.pdf innate immunity MERS-CoV SARS-CoV severe acute respiratory" exact="syndrome" post="virology Funding National Institutes of Health10.13039/100000002 Division of Cancer"/>
 <result pre="respiratory syndrome virology Funding National Institutes of Health10.13039/100000002 Division of" exact="Cancer" post="Epidemiology and Genetics, National Cancer Institute10.13039/100011541 page-count: (See the"/>
 <result pre="Institutes of Health10.13039/100000002 Division of Cancer Epidemiology and Genetics, National" exact="Cancer" post="Institute10.13039/100011541 page-count: (See the Major Article by Chu et"/>
 <result pre="Major Article by Chu et al on pages 1400â€&quot;9.) Coronavirus" exact="disease" post="2019 (COVID-19), a respiratory illness caused by a novel"/>
 <result pre="et al on pages 1400â€&quot;9.) Coronavirus disease 2019 (COVID-19), a" exact="respiratory" post="illness caused by a novel coronavirus, was first identified"/>
 <result pre="The etiologic agent of COVID-19 is a Î²-coronavirus called severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] that is closely"/>
 <result pre="etiologic agent of COVID-19 is a Î²-coronavirus called severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [1] that is closely related"/>
 <result pre="agent of COVID-19 is a Î²-coronavirus called severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [1] that is closely related to"/>
 <result pre="coronavirus 2 (SARS-CoV-2) [1] that is closely related to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV), the virus that caused the"/>
 <result pre="2 (SARS-CoV-2) [1] that is closely related to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV), the virus that caused the much"/>
 <result pre="(SARS-CoV-2) [1] that is closely related to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV), the virus that caused the much more"/>
 <result pre="syndrome coronavirus (SARS-CoV), the virus that caused the much more" exact="limited" post="SARS outbreak of 2002â€&quot;2003, and to Middle East respiratory"/>
 <result pre="more limited SARS outbreak of 2002â€&quot;2003, and to Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), the etiologic agent for MERS. SARS-CoV-2"/>
 <result pre="limited SARS outbreak of 2002â€&quot;2003, and to Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), the etiologic agent for MERS. SARS-CoV-2 differs"/>
 <result pre="important ways. The case fatality rate for COVID-19 is considerably" exact="lower" post="than that reported for SARS (17%) or MERS (40%)"/>
 <result pre="however, SARS-CoV-2 spread much more rapidly, quickly causing many more" exact="total" post="deaths than infection with both previous coronaviruses combined. Currently,"/>
 <result pre="much more rapidly, quickly causing many more total deaths than" exact="infection" post="with both previous coronaviruses combined. Currently, there are no"/>
 <result pre="SARS-CoV-2 is limited. A report in this issue of Clinical" exact="Infectious" post="Diseases from Professor Kwok-Yung Yuen and colleagues demonstrates that"/>
 <result pre="is limited. A report in this issue of Clinical Infectious" exact="Diseases" post="from Professor Kwok-Yung Yuen and colleagues demonstrates that SARS-CoV-2"/>
 <result pre="weak expression of interferons (IFNs) in infected cells [3]. This" exact="absence of" post="IFN production likely hampers the early innate immune response"/>
 <result pre="SARS-CoV-2 and divided each sample into 2 subcultures to compare" exact="viral" post="replication and immune activation caused by experimental infection with"/>
 <result pre="to compare viral replication and immune activation caused by experimental" exact="infection" post="with SARS-CoV-2 to that for SARS-CoV [3]. This self-paired"/>
 <result pre="(types I and II pneumocytes, as well as alveolar macrophages)," exact="infection" post="and viral replication was much more efficient for SARS-CoV-2"/>
 <result pre="and II pneumocytes, as well as alveolar macrophages), infection and" exact="viral" post="replication was much more efficient for SARS-CoV-2 than SARS-CoV."/>
 <result pre="was much more efficient for SARS-CoV-2 than SARS-CoV. The higher" exact="viral" post="levels associated with SARS-CoV-2 infection may reflect an even"/>
 <result pre="SARS-CoV-2 than SARS-CoV. The higher viral levels associated with SARS-CoV-2" exact="infection" post="may reflect an even more striking observation from this"/>
 <result pre="IFNs play a crucial role in the immune response to" exact="viral" post="infections. Type I IFNs, such as IFN-Î± and IFN-Î²,"/>
 <result pre="a crucial role in the immune response to viral infections." exact="Type I" post="IFNs, such as IFN-Î± and IFN-Î², attach to cell"/>
 <result pre="ISGs mediate antiviral activities. The IFN-Î» family (also known as" exact="type III" post="interferons) [4â€&quot;6] is a more recently discovered group of"/>
 <result pre="receptor (IFN-Î»R1) is largely restricted to cells and tissues of" exact="epithelial" post="origin, including respiratory epithelial cells [4, 5]. It is"/>
 <result pre="largely restricted to cells and tissues of epithelial origin, including" exact="respiratory" post="epithelial cells [4, 5]. It is increasingly believed that"/>
 <result pre="restricted to cells and tissues of epithelial origin, including respiratory" exact="epithelial" post="cells [4, 5]. It is increasingly believed that IFN-Î»s"/>
 <result pre="increasingly believed that IFN-Î»s provide important first-line immunological defense against" exact="viral" post="infections of the respiratory tract [7â€&quot;11]. In murine models,"/>
 <result pre="believed that IFN-Î»s provide important first-line immunological defense against viral" exact="infections" post="of the respiratory tract [7â€&quot;11]. In murine models, IFN-Î»s"/>
 <result pre="provide important first-line immunological defense against viral infections of the" exact="respiratory" post="tract [7â€&quot;11]. In murine models, IFN-Î»s are the first"/>
 <result pre="IFN-Î»s are the first IFNs produced in response to influenza" exact="virus infection" post="and these cytokines act at the epithelial barrier to"/>
 <result pre="are the first IFNs produced in response to influenza virus" exact="infection" post="and these cytokines act at the epithelial barrier to"/>
 <result pre="to influenza virus infection and these cytokines act at the" exact="epithelial" post="barrier to suppress initial viral spread without causing inflammation"/>
 <result pre="these cytokines act at the epithelial barrier to suppress initial" exact="viral" post="spread without causing inflammation [9, 11]. Mice lacking IFN-Î»R1"/>
 <result pre="without causing inflammation [9, 11]. Mice lacking IFN-Î»R1 shed more" exact="infectious" post="virus particles and transmit the virus to other mice"/>
 <result pre="treatment with recombinant IFN-Î» inhibits influenza virus replication, protects the" exact="upper" post="airways, and blocks virus transmission to uninfected mice [9â€&quot;11]."/>
 <result pre="especially true of coronaviruses. In a related previous study, experimental" exact="infection" post="with a MERS-CoV strain (human coronavirus EMC) failed to"/>
 <result pre="MERS-CoV strain (human coronavirus EMC) failed to induce expression of" exact="type I" post="and type III IFNs in respiratory tissue cultures, while"/>
 <result pre="coronavirus EMC) failed to induce expression of type I and" exact="type III" post="IFNs in respiratory tissue cultures, while infection with influenza"/>
 <result pre="induce expression of type I and type III IFNs in" exact="respiratory" post="tissue cultures, while infection with influenza virus induced high"/>
 <result pre="I and type III IFNs in respiratory tissue cultures, while" exact="infection" post="with influenza virus induced high levels of both IFN"/>
 <result pre="previous work from Professor Yuenâ€™s group, neither MERS-CoV nor SARS-CoV" exact="infection" post="induced significant expression of type I IFNs in human"/>
 <result pre="group, neither MERS-CoV nor SARS-CoV infection induced significant expression of" exact="type I" post="IFNs in human monocyteâ€&quot;derived macrophages [13]. The current report"/>
 <result pre="as yet no data with respect to treatment of SARS-CoV-2" exact="infection" post="with IFN-Î»; however, there are relevant data concerning SARS-CoV"/>
 <result pre="infected with SARS-CoV, prophylactic treatment with intramuscular pegylated IFN-Î± reduced" exact="viral" post="replication and excretion, as well as pulmonary damage [14]."/>
 <result pre="pegylated IFN-Î± reduced viral replication and excretion, as well as" exact="pulmonary" post="damage [14]. In a human airway epithelial cell culture"/>
 <result pre="as well as pulmonary damage [14]. In a human airway" exact="epithelial" post="cell culture model, IFN-Î»3 and IFN-Î»4 exhibited antiviral effects"/>
 <result pre="animals receiving pegylated IFN-Î± after exposure to SARS-CoV had outcomes" exact="intermediate" post="between the prophylactically treated group and untreated controls [14]."/>
 <result pre="untreated controls [14]. Most studies of treatment for severe MERS-CoV" exact="infection" post="have not shown an association of IFN-Î± therapy with"/>
 <result pre="have not shown an association of IFN-Î± therapy with overall" exact="disease" post="outcomes [17]. However, a recurrent theme with all anti-infective"/>
 <result pre="of IFN-Î± therapy with overall disease outcomes [17]. However, a" exact="recurrent" post="theme with all anti-infective drugs is that the time"/>
 <result pre="In phase 2 and 3 clinical trials of patients with" exact="chronic hepatitis C" post="virus (HCV) infection, pegylated IFN-Î»1 administered parenterally for up"/>
 <result pre="phase 2 and 3 clinical trials of patients with chronic" exact="hepatitis C" post="virus (HCV) infection, pegylated IFN-Î»1 administered parenterally for up"/>
 <result pre="but similar efficacy, compared with pegylated IFN-Î± [18, 19]. The" exact="lower" post="frequency of hematologic adverse events in patients who were"/>
 <result pre="infections. Currently, pegylated IFN-Î»1 is being tested for treatment of" exact="hepatitis D" post="virus infection, including in a clinical trial now under"/>
 <result pre="pegylated IFN-Î»1 is being tested for treatment of hepatitis D" exact="virus infection," post="including in a clinical trial now under way at"/>
 <result pre="Health Clinical Center (NCT03600714) [21]. The data on IFN-Î» and" exact="respiratory" post="infections may have important clinical and public health implications."/>
 <result pre="Clinical Center (NCT03600714) [21]. The data on IFN-Î» and respiratory" exact="infections" post="may have important clinical and public health implications. The"/>
 <result pre="be anticipated for such emerging epidemics. The adverse effects of" exact="type I" post="IFNs may limit their use for widespread intervention, as"/>
 <result pre="Health Organization Solidarity trial [22]; however, adverse effects are notably" exact="lower" post="with pegylated IFN-Î»1 [18]. Pegylated IFN-Î»1 might be deployed"/>
 <result pre="animal model studies suggest that pegylated IFN-Î»1 might reduce the" exact="disease" post="severity and risk of transmission of SARS-CoV-2. While more"/>
 <result pre="as part of an early and rapid response to attenuate" exact="disease" post="and prevent infection spread. As the pathogenesis of COVID-19"/>
 <result pre="an early and rapid response to attenuate disease and prevent" exact="infection" post="spread. As the pathogenesis of COVID-19 is incompletely understood,"/>
 <result pre="pegylated IFN-Î»1 administration require careful study. An important difference between" exact="chronic" post="viral hepatitis, where pegylated IFN-Î»1 has been tested so"/>
 <result pre="IFN-Î»1 administration require careful study. An important difference between chronic" exact="viral hepatitis," post="where pegylated IFN-Î»1 has been tested so far, and"/>
 <result pre="where pegylated IFN-Î»1 has been tested so far, and SARS-CoV-2" exact="infection" post="is that patients with severe COVID-19 have a high"/>
 <result pre="that patients with severe COVID-19 have a high degree of" exact="lung inflammation." post="While IFN-Î» has weaker proinflammatory properties than type I"/>
 <result pre="of lung inflammation. While IFN-Î» has weaker proinflammatory properties than" exact="type I" post="IFN, pegylated IFN-Î»1 has not been tested in patients"/>
 <result pre="IFN, pegylated IFN-Î»1 has not been tested in patients with" exact="respiratory" post="infections and, ideally, should be first studied in patients"/>
 <result pre="pegylated IFN-Î»1 has not been tested in patients with respiratory" exact="infections" post="and, ideally, should be first studied in patients with"/>
 <result pre="ideally, should be first studied in patients with early SARS-CoV-2" exact="infection" post="or as prophylaxis. Possible trials of pegylated IFN-Î»1 for"/>
 <result pre="Human Services, the National Institutes of Health (NIH), the National" exact="Cancer" post="Institute (NCI), or the Food and Drug Administration, nor"/>
 <result pre="the Intramural Research Program of the NIH, NCI, Division of" exact="Cancer" post="Epidemiology and Genetics. Potential conflicts of interest. T. R."/>
 <result pre="new interferon gene IFNL4 is associated with impaired clearance of" exact="hepatitis C" post="virus. Nat Genet2013; 45:164â€&quot;71.23291588 7.MordsteinM, KochsG, DumoutierL, et al.Interferon-lambda"/>
 <result pre="PLoS Pathog2008; 4:e1000151.18787692 8.CrottaS, DavidsonS, MahlakoivT, et al.Type I and" exact="type III" post="interferons drive redundant amplification loops to induce a transcriptional"/>
 <result pre="EleminiadouEE, et al.Interferon-Î» mediates non-redundant front-line antiviral protection against influenza" exact="virus infection" post="without compromising host fitness. Immunity2017; 46:875â€&quot;90.e6.28514692 10.KlinkhammerJ, SchnepfD, YeL,"/>
 <result pre="et al.Interferon-Î» mediates non-redundant front-line antiviral protection against influenza virus" exact="infection" post="without compromising host fitness. Immunity2017; 46:875â€&quot;90.e6.28514692 10.KlinkhammerJ, SchnepfD, YeL,"/>
 <result pre="SchnepfD, YeL, et al.IFN-lambda prevents influenza virus spread from the" exact="upper" post="airways to the lungs and limits virus transmission. Elife2018;"/>
 <result pre="novel human betacoronavirus lineage C virus in human ex vivo" exact="respiratory" post="organ cultures. J Virol2013; 87:6604â€&quot;14.23552422 13.ZhouJ, ChuH, LiC, et"/>
 <result pre="87:6604â€&quot;14.23552422 13.ZhouJ, ChuH, LiC, et al.Active replication of Middle East" exact="respiratory" post="syndrome coronavirus and aberrant induction of inflammatory cytokines and"/>
 <result pre="13.ZhouJ, ChuH, LiC, et al.Active replication of Middle East respiratory" exact="syndrome" post="coronavirus and aberrant induction of inflammatory cytokines and chemokines"/>
 <result pre="Infect Dis2014; 209:1331â€&quot;42.24065148 14.HaagmansBL, KuikenT, MartinaBE, et al.Pegylated interferon-alpha protects" exact="type 1" post="pneumocytes against SARS coronavirus infection in macaques. Nat Med2004;"/>
 <result pre="et al.Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaques. Nat Med2004; 10:290â€&quot;3.14981511 15.HammingOJ, TerczyÅ&quot;ska-DylaE, VieyresG, et"/>
 <result pre="et al.Efficient replication of the novel human betacoronavirus EMC on" exact="primary" post="human epithelium highlights its zoonotic potential. mBio2013; 4:e00611â€&quot;12. 17.MorraME,"/>
 <result pre="et al.Clinical outcomes of current medical approaches for Middle East" exact="respiratory" post="syndrome: a systematic review and meta-analysis. Rev Med Virol2018;"/>
 <result pre="interferon lambda 1 with or without ribavirin in patients with" exact="chronic" post="genotype 1 hepatitis C virus infection. Hepatology2010; 52:822â€&quot;32.20564352 19.MuirAJ,"/>
 <result pre="with or without ribavirin in patients with chronic genotype 1" exact="hepatitis C" post="virus infection. Hepatology2010; 52:822â€&quot;32.20564352 19.MuirAJ, AroraS, EversonG, et al.collab:"/>
 <result pre="without ribavirin in patients with chronic genotype 1 hepatitis C" exact="virus infection." post="Hepatology2010; 52:822â€&quot;32.20564352 19.MuirAJ, AroraS, EversonG, et al.collab: EMERGE Study"/>
 <result pre="phase 2b study of peginterferon lambda-1a for the treatment of" exact="chronic" post="HCV infection. J Hepatol2014; 61:1238â€&quot;46.25064437 20.DickensheetsH, SheikhF, ParkO, GaoB,"/>
</results>
